Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07203053) titled 'A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: ETOP IBCSG Partners Foundation
Condition:
Extensive Stage Lung Small Cell Cancer
Intervention:
Drug: Tarlatamab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: May 2026
Target Sample Size: 48
To know more, visit https://clinicaltrials.gov/study/NCT07203053
Published by HT Digi...